Azithromycin/dexamethasone - InSite Vision
Alternative Names: AzaSite Otic; AzaSite Plus; ISV-016; ISV-502Latest Information Update: 08 Aug 2019
At a glance
- Originator InSite Vision
- Class Anti-inflammatories; Antibacterials; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Macrolides; Pregnadienetriols
- Mechanism of Action Glucocorticoid receptor agonists; Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Blepharitis
- Discontinued Otitis externa; Otitis media
Most Recent Events
- 08 Aug 2019 No development reported - Phase-III for Blepharitis in USA (Topical)
- 03 Nov 2015 InSite Vision became an indirect wholly owned subsidiary of Sun Pharma
- 03 Nov 2015 InSite Vision has been acquired by Sun Pharmaceutical Industries